🔗 Share this article The Global Health Body Raises Warning Over Acute Scarcity of Weight-Loss Jabs Under 10% of individuals that would benefit from GLP-1 drugs such as Wegovy have access to them, warns the global health agency as it releases its first recommendations on the therapies. Considering over a billion people worldwide now classified as obese, it is calling for more widespread and fairer availability to this class of drugs. Based on estimates, over two billion will be living with obesity by 2030 if no action is taken. "The latest guidelines affirms that obesity is a lifelong illness that can be treated with thorough and ongoing care," remarked WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and logistical bottlenecks are key barriers to widespread availability to the jabs that can aid individuals in losing considerable body mass, says the organization. Weight-Loss Drug Supply Crisis Even under the present best projected scenario, the production of such drugs could only cover around 100 million people – fewer than 10% of those who need them, per the health organization. The advice calls on governments and firms to expand availability, by measures such as voluntary licensing. A patent on a key compound – the main ingredient of a leading brand – is set to lapse in multiple nations in 2026. How Weight-Loss Jabs Function The injections imitate a body's own hormone to delay gastric emptying, reduce hunger and boost the sense of being full so people consume fewer calories. Individuals typically begin shedding pounds in the initial weeks of commencing the weekly injections. Evidence indicates patients may regain a significant portion after a year of discontinuing the drug, when their normal appetite resume. Being above a healthy weight increases your chance for experiencing diseases, such as type 2 diabetes, heart disease, stroke, and some cancers. Excess weight affects people in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, as per the WHO.
Under 10% of individuals that would benefit from GLP-1 drugs such as Wegovy have access to them, warns the global health agency as it releases its first recommendations on the therapies. Considering over a billion people worldwide now classified as obese, it is calling for more widespread and fairer availability to this class of drugs. Based on estimates, over two billion will be living with obesity by 2030 if no action is taken. "The latest guidelines affirms that obesity is a lifelong illness that can be treated with thorough and ongoing care," remarked WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and logistical bottlenecks are key barriers to widespread availability to the jabs that can aid individuals in losing considerable body mass, says the organization. Weight-Loss Drug Supply Crisis Even under the present best projected scenario, the production of such drugs could only cover around 100 million people – fewer than 10% of those who need them, per the health organization. The advice calls on governments and firms to expand availability, by measures such as voluntary licensing. A patent on a key compound – the main ingredient of a leading brand – is set to lapse in multiple nations in 2026. How Weight-Loss Jabs Function The injections imitate a body's own hormone to delay gastric emptying, reduce hunger and boost the sense of being full so people consume fewer calories. Individuals typically begin shedding pounds in the initial weeks of commencing the weekly injections. Evidence indicates patients may regain a significant portion after a year of discontinuing the drug, when their normal appetite resume. Being above a healthy weight increases your chance for experiencing diseases, such as type 2 diabetes, heart disease, stroke, and some cancers. Excess weight affects people in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, as per the WHO.